Brief: Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
05/11/2025 13:41
Nov 5 (Reuters) - Pacira Biosciences Inc PCRX.O: PACIRA BIOSCIENCES CONCLUDES PATIENT ENROLLMENT IN PART A OF PHASE 2 STUDY EVALUATING SAFETY AND EFFICACY OF PCRX-201 FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE Source text: ID:nGNX3PnPwm Further company coverage: PCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pacira Biosciences
See all newsBrief: Pacira Biosciences Inc - Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "For" All Of Pacira's Director Nominees
Brief: Pacira Biosciences Urges Stockholders To Vote "For" Election Of Pacira's Nominees On Blue Proxy Card
Brief: Doma Perpetual Urges Pacira Biosciences Shareholders To Judge Sale Price Adequacy
Brief: Doma Perpetual Capital Management Calls For Removal Of Pacira CEO And Strategic Sale
Brief: Pacira Biosciences Sends Letter To Stockholders Reiterating Superior Qualifications Of Its Board Nominees